We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avacta and Integumen Collaborate for Detection of SARS-COV-2 in Wastewater
Product News

Avacta and Integumen Collaborate for Detection of SARS-COV-2 in Wastewater

Avacta and Integumen Collaborate for Detection of SARS-COV-2 in Wastewater
Product News

Avacta and Integumen Collaborate for Detection of SARS-COV-2 in Wastewater

Credit: Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Avacta and Integumen Collaborate for Detection of SARS-COV-2 in Wastewater"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, has entered into a collaboration with Integumen plc (Integumen) to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in waste water, to provide a real-time alert system to warn of localized COVID-19 outbreaks.

Over 60 percent of COVID-19 positive patients had gastrointestinal symptoms, such as diarrhea, nausea and vomiting, and the SARS-COV-2 virus was found in their fecal samples. Sampling wastewater from households may therefore provide an early warning system for localized outbreaks in communities.

Recently, Avacta announced that it had generated a number of highly specific Affimer reagents that detect the SARS-COV-2 virus spike protein for use in diagnostic tests and in neutralizing therapies.

The collaboration with Integumen aims to evaluate some of these Affimer reagents in next-generation sensors, based on the real-time bacteria detection and alert system1 developed by Rinocloud Ltd, a subsidiary of Integumen, with the aim of integrating these sensors into Modern Water plc’s Microtox water contamination system to detect the coronavirus. The award-winning Microtox system, which can detect the presence of contaminating bacteria, virus and toxins, is distributed by Modern Water and has a global footprint of over 3,000 installations. The proposed Affimer sensors would be consumable items to be replaced on a roughly monthly basis.

Once initial testing of the Affimer reagents is completed over the next few weeks, validation of the sensors will be carried out using SARS-COV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen. Upon successful completion of this evaluation, Integumen and Avacta will enter into a supply agreement to allow Integumen to manufacture and commercialize the wastewater detection sensors globally by retrofitting into Microtox systems.

Advertisement